{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:36:00Z","timestamp":1777775760248,"version":"3.51.4"},"reference-count":9,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,13]]},"DOI":"10.1182\/blood.2020009850","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T15:35:30Z","timestamp":1620920130000},"page":"2570-2571","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes for PTCL: which pathway to success?"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2021051315352216200_B1","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"18","key":"2021051315352216200_B2","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"10168","key":"2021051315352216200_B3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2019;393(10168):228]","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"2021051315352216200_B4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122781","article-title":"An exploratory analysis of brentuximab vedotin plus CHP (A + CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant [abstract]","volume":"134","author":"Savage","year":"2019","journal-title":"Blood"},{"key":"2021051315352216200_B5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/hon.2439_190","article-title":"Phase I\/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T cell non-Hodgkin lymphoma: Phase I results from the T-cell consortium","volume":"35","author":"Lunning","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"2021051315352216200_B6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomized phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"9980","key":"2021051315352216200_B7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2015;386(9993):532]","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"2021051315352216200_B8","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"29","key":"2021051315352216200_B9","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/19\/2570\/1807106\/bloodbld2020009850c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/19\/2570\/1807106\/bloodbld2020009850c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T15:35:41Z","timestamp":1620920141000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/19\/2570\/475923\/Outcomes-for-PTCL-which-pathway-to-success"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":9,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,5,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009850","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]}}}